Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care
暂无分享,去创建一个
S. Vesely | J. George | G. Raskob | T. Guthrie | E. Cobos | R. Lyons | P. Klug | D. Moore | B. L. Towell | B. Towell | Sara K. Vesely | Brenda L. Towell
[1] S. Vesely,et al. Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001 , 2003, Journal of pediatric hematology/oncology.
[2] V. Blanchette,et al. Immune thrombocytopenic purpura. , 2002, The New England journal of medicine.
[3] J. Bussel,et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? , 2002, Blood.
[4] D. Karakasis,et al. Short-course corticosteroid-induced pulmonary and apparent cerebral aspergillosis in a patient with idiopathic thrombocytopenic purpura. , 2001, Blood.
[5] R. Westendorp,et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. , 2001, Blood.
[6] J. Bussel,et al. A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura , 2001 .
[7] R. Golub,et al. The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. , 2000, Seminars in hematology.
[8] K. Schmidt,et al. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.
[9] M. Prins,et al. Bleeding Classification in Clinical Trials: Observer Variability and Clinical Relevance , 1997, Thrombosis and Haemostasis.
[10] I. Moon,et al. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines , 1997, The Lancet.
[11] J. George,et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.
[12] P. Jacobs,et al. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. , 1994, The American journal of medicine.
[13] S. Israels,et al. A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. , 1992, The Journal of pediatrics.
[14] J M Lachin,et al. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.
[15] B. Bouroncle,et al. IDIOPATHIC AND SECONDARY THROMBOCYTOPENIC PURPURA: CLINICAL STUDY AND EVALUATION OF 381 CASES OVER A PERIOD OF 28 YEARS , 1960 .